Kshiti Dholakia to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Kshiti Dholakia has written about Drug Resistance, Neoplasm.
Connection Strength
0.172
-
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. Mol Cancer Ther. 2022 02; 21(2):322-335.
Score: 0.138
-
Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 Sep; 13(609):eabb3738.
Score: 0.034